Incyte is a buy after a transformative 2025 year, with revenue climbing to $5.14 billion and diluted EPS surging to $6.41, placing the stock at a discounted P/E of just 13.5x versus a peer median of 21.9x. The company generated $1.36 billion in free cash flow, underpinning pipeline investments including the planned mid-year Phase 3 start for CALR antibody 989. A sharp jump in smart-money ownership to a score of 0.4082 and 44 funds signals institutional conviction, while the stock consolidates constructively above its 50- and 200-day moving averages.
JAKAFI revenue concentration
A dominant share of revenue likely comes from JAKAFI, exposing INCY to future biosimilar competition or patent expiry.
Pipeline binary risk
The upcoming Phase 3 trial for CALR antibody 989 is a key catalyst; clinical failure could significantly impair the growth narrative.
Margin normalization
The 92.7% gross margin in 2025 may have been boosted by milestone payments; any mean reversion could compress earnings.
Insider profit-taking
Executive Paul Clancy sold shares at $94.93 following option exercises, which may reflect near-term caution despite overall long-term positioning.